Chitosan Hemostat Patents: Top Companies & Filing Trends 2026
Chitosan and Polysaccharide Hemostat Patents: Who Files, and Where Claims Concentrate
55.6% of all 198 records sit with just five assignees, and 85.4% with ten — this is a field with a narrow set of gatekeepers, not a fragmented one. Filings rose from 7 in 2017 to a peak of 35 in 2018, and the 2021-to-2024 span — the last window unaffected by publication lag — shows growth from 2 to 3 records, a +50% increase. Years after 2024 are still filling in and should not be read as a slowdown.
- 1TRICOL BIOMEDICAL INC37
- 2NORTH CAROLINA STATE UNIV21
- 3LOMA LINDA UNIV MEDICAL CENT20
- 4FOSHAN UNITED MEDICAL TECH18
- 5LOMA LINDA UNIVERSITY14
See the full chitosan and polysaccharide hemostats analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents on chitosan hemostat dressings?
The ranking in this dataset covers 66 assignees across 198 records, and it is heavily front-loaded: the leading assignee alone holds 37 records, more than double the count at fifth place (14). The top five assignees combined hold 55.6% of all 198 records, and the top ten hold 85.4%. This means the vast majority of the remaining 56-plus ranked companies each hold only a small handful of filings, forming a long tail behind a small group of established filers.
Is chitosan hemostat technology still an active area for new patents?
Filing activity peaked in 2018 at 35 records and cooled in the years after, but the 2021-to-2024 window — the last period not distorted by publication lag — shows a +50% increase, from 2 to 3 records. Because publication typically lags actual filing by around 18 months, the years closest to the 2026 data cut-off will understate real activity and should not be read as a decline. The underlying trend is one of renewed, if modest, growth rather than an exit from the category.
What technical areas are most heavily claimed in this space?
Sterilising and disinfecting functionality (IPC class A61L) is by far the most claimed area, appearing in 78.3% of the 198 records in scope. Implant and prosthesis-related claims (A61F) and medicinal preparation claims (A61K) each appear in roughly a third of records, at 31.8% and 31.3% respectively. Claims specific to the polysaccharide chemistry itself, under C08B, appear in only 8.6% of records, indicating that most patent activity protects the dressing’s clinical function rather than the base polymer science.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Chitosan and Polysaccharide Hemostats covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.